BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
288 hedge funds and large institutions have $8.48B invested in bluebird bio in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 108 increasing their positions, 99 reducing their positions, and 54 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
6% less funds holding
Funds holding: 307 → 288 (-19)
31% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 54
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
288
Holding in Top 10
2
Calls
$177M
Puts
$151M
Top Buyers
| 1 | +$311M | |
| 2 | +$207M | |
| 3 | +$136M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$88.4M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$72.2M |
Top Sellers
| 1 | -$54M | |
| 2 | -$53.8M | |
| 3 | -$29.2M | |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$29M |
| 5 |
Citigroup
New York
|
-$26M |